New Opportunity for COVID Therapeutics by Eric Jia-Sobota
For the past 18 months companies have been confused and frustrated by the shifting USG policies regarding the development of therapeutics as part of the COVID-19 response. BARDA was back and forth as parts of the BAA were suspended, unsuspended, and resuspended. The American rescue Plan legislation was passed about six months ago and although […]
New Opportunity for COVID Therapeutics by Eric Jia-Sobota Read More »
